HMGBiotech is a biotech company founded by Marco E. Bianchi, a leading scientist in the HMGB field.

HMGB1 is a component of the cell nucleus, with multiple functions in the organization and expression of the genome. When a cell dies because of an insult (a virus, a mechanical or chemical trauma, poisoning) HMGB1 is released and is picked up by receptors in nearby cells. In addition, cells under severe stress secrete HMGB1 even before dying. Surviving cells mount a firstline response -inflammation- and try to replace the dead cells and reconstruct the damaged tissue. HMGB1 promotes recovery and regeneration, for example of the heart after infarction. However, too much HMGB1 is associated to sepsis (excessive inflammation leading to acute distress and eventually death), arthritis, atherosclerosis, and cancer metastasis.

HMGBiotech srl provides reagents, services and ideas to other researchers and companies active in this promising field. It also helps the Bianchi lab in developing assays and reagents.

HMGBiotech has R&D and production unit within OSR in via Olgettina 58, 20133 Milano, Italy

HMGBiotech是一家生物技術(shù)公司，由HMGB領(lǐng)域的領(lǐng)先科學(xué)家馬可·E·比安奇創(chuàng)立。
HMGB1是細(xì)胞核的一個(gè)組成部分，在基因組的組織和表達(dá)中具有多種功能。當(dāng)一個(gè)細(xì)胞因侮辱（病毒、機(jī)械或化學(xué)創(chuàng)傷、中毒）而死亡時(shí)，HMGB1被釋放，并被附近細(xì)胞的受體攝取。此外，處于嚴(yán)重壓力下的細(xì)胞甚至在死亡之前就分泌HMGB1。存活的細(xì)胞會(huì)產(chǎn)生第一線反應(yīng)——炎癥，并試圖替換死亡細(xì)胞，重建受損組織。HMGB1促進(jìn)恢復(fù)和再生，例如梗死后的心臟。然而，過多的HMGB1與敗血癥（過度炎癥導(dǎo)致急性窘迫并最終死亡）、關(guān)節(jié)炎、動(dòng)脈粥樣硬化和癌癥轉(zhuǎn)移有關(guān)。
HMGBiotech srl為活躍在這一有希望的領(lǐng)域的其他研究人員和公司提供試劑、服務(wù)和想法。它還幫助Bianchi實(shí)驗(yàn)室開發(fā)分析和試劑。
HMGBiotech在意大利米蘭via Olgettina 5820133的OSR內(nèi)設(shè)有研發(fā)和生產(chǎn)部門